Lipid Therapeutics GmbH
Lipid Therapeutics is a biopharmaceutical company focused on the development and commercialization of phospholipids. The company was set-up and financed in 2008 by the EMBL Technology Fund to commercialize the scientific work of Prof. Wolfgang Stremmel, Krehl University Clinic in Heidelberg, Germany. Lipid Therapeutics’ mission is to develop novel therapies for inflammatory diseases of the digestive system. The company's current focus is to develop LT-02, a retard formulation of phosphatidylcholine, for the treatment of Ulcerative Colitis.